Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325747 | 1.00 | KMT2A (0.47) | KMT2AGAAALDH1A1LMNARECQL | |
| SCHEMBL2081536 | 1.00 | KMT2A (0.47) | KMT2AGAAALDH1A1LMNARECQL | |
| SCHEMBL11088444 | 0.94 | KMT2A (0.43) | KMT2AGAAALDH1A1LMNARECQL | |
| SCHEMBL10843839 | 0.90 | GAA (0.47) | KMT2AGAAALDH1A1LMNARECQL | |
| SCHEMBL21118959 | 0.89 | KMT2A (0.40) | KMT2AGAAALDH1A1LMNARECQL | |
| SCHEMBL10710330 | 0.88 | KMT2A (0.38) | KMT2AGAAALDH1A1LMNARECQL | |
| SCHEMBL14258470 | 0.88 | LMNA (0.43) | KMT2AGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9017494 | 0.87 | LMNA (0.47) | KMT2AGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28453248 | 0.87 | ALDH1A1 (0.41) | KMT2AGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL28453243 | 0.87 | ALDH1A1 (0.41) | KMT2AGAAALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022161414-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATION THEREOF | 成都茵创园医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2548874-A2 | Substituted piperazines as CB1 antagonists | Intervet International B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-8101779-B2 | Enantioselective synthesis of (+) and (–)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101779-B2 | Enantioselective synthesis of (+) and (–)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100087657-A1 | ENANTIOSELECTIVE SYNTHESIS OF (+) AND (-)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]-1,3-DIAZACYCLOPENT-2-3ENE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087657-A1 | ENANTIOSELECTIVE SYNTHESIS OF (+) AND (-)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]-1,3-DIAZACYCLOPENT-2-3ENE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-04-08 | — | — | US | disclosed |
| EP-0315008-B1 | DERIVATIVES OF (6-(HETERO)ARYLOXY-NAPHTHALIN-2-YL-OXY)ALCANOIC ACID | BAYER AG (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0453846-A2 | Aryloxycarbonyl compounds | BAYER AG (DE) | 1991-10-30 | — | — | EP | disclosed |
| EP-0309864-B1 | ALPHA-(5-ARYLOXY-NAPHTHALEN-1-YL-OXY)-PROPIONIC-ACID DERIVATIVES | BAYER AG (DE) | 1991-05-22 | — | — | EP | disclosed |
| EP-0347679-A1 | 1,7-Dioxynaphthalene derivatives | BAYER AG (DE) | 1989-12-27 | — | — | EP | disclosed |
| US-4889851-A | BONE DISORDERS | FUJISAWA PHARMACEUTICAL CO, LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0315008-A2 | Derivatives of (6-(hetero)aryloxy-naphthalin-2-yl-oxy)alcanoic acid | BAYER AG (DE) | 1989-05-10 | — | — | EP | disclosed |
| EP-0308755-A2 | Derivatives of 7-(hetero)aryloxy-naphthalen-2-yloxy)alcanoic acid | BAYER AG (DE) | 1989-03-29 | — | — | EP | disclosed |
| EP-0179015-B1 | 7-(ARYLOXY)-2-NAPHTHOXYALKANECARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION OF THESE COMPOUNDS, AS WELL AS AGENTS HAVING HERBICIDAL ACTIVITY CONTAINING THESE COMPOUNDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-13 | — | — | EP | disclosed |
| US-4709077-A | 7-(aryloxy)-2-naphthoxyalkanecarboxylic acid derivatives, processes for the preparation of these compounds, as well as agents having herbicidal activity containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-11-24 | — | — | US | disclosed |
| EP-0179015-A1 | 7-(Aryloxy)-2-naphthoxyalkanecarboxylic acid derivatives, processes for the preparation of these compounds, as well as agents having herbicidal activity containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087657-A1 | ENANTIOSELECTIVE SYNTHESIS OF (+) AND (-)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL]-1,3-DIAZACYCLOPENT-2-3ENE | CYP2E1, CYP2D6, CYP2C9 | KMT2A 796/4885GAA 2065/4885ALDH1A1 157/4885 |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | KMT2A 2974/4885GAA 3652/4885ALDH1A1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.